Earnings call transcript: Merck KGaA Q4 2025 misses EPS forecast, stock drops

Merck reported Q4 EPS €1.88 vs €1.96 expected (−4.08% surprise) and revenue €5.249bn vs €5.28bn (−0.57% surprise), triggering a 10.21% pre-market share drop to €110.35. Organic growth was +2.6% while reported sales fell −3.1% YoY due to FX headwinds (~€318m); EBITDA pre was €1.443bn with a stable margin of 27.5% and operating cash flow rose +4.9% to €1.291bn. Management kept the dividend at €2.20 and issued 2026 guidance of €20.0–21.1bn sales, €5.5–6.0bn EBITDA pre and EPS pre €7.10–8.00, but the outlook is conservative (assumes no U.S. MAVENCLAD sales from March). Key near-term risks are FX volatility, oncology competition and regulatory/timing uncertainties; technically the stock appears oversold but faces tangible downside until clarity on MAVENCLAD and FX effects.

Analysis

The price action is driven more by positioning and convexity than by a structural earnings collapse — the pre-open gap amplified delta- and gamma- hedging flows and likely forced mark-to-market adjustments in volatility-sensitive funds. That creates a high-probability mean-reversion window over days-to-weeks as short-dated option gamma decays, but it also exposes holders to a multi-week liquidity vacuum if sell-side research turns uniformly cautious.

Currency translation is the overlooked lever that will re-rate reported results independent of operating performance: the company’s translation sensitivity means a sustained USD rebound (or stabilization versus EUR/other APAC currencies) is capable of flipping reported growth and EPS narratives without any underlying organic acceleration. That makes FX the dominant risk/catalyst over the next two quarters — hedging behavior by corporates and central bank moves in Asia are therefore direct drivers of stock-level volatility.

On fundamentals, the firm’s move into higher-margin, less cyclical end-markets (bioprocess consumables and advanced materials for AI chips) produces asymmetric upside if execution holds; conversely, the concentrated oncology/neurology franchises and near-term regulatory binaries create single-event downside that would crystallize over months rather than days. Finally, M&A optionality and disciplined capital allocation (dividend continuity, deleveraging runway) are credible multi-quarter support factors that the market will re-price once quarterly headwinds normalize.

Key Decisions for Investors

• Tactical long Merck KGaA (0O14): initiate a 3% NAV long below EUR 115 with a 6–12 month horizon. Target +25% if FX normalizes and process/materials momentum continues; hard stop at -10%. Rationale: capture beta to operational recovery while using a tight stop to limit downside from regulatory/generic shocks.
• Structured call spread to exploit asymmetric recovery: buy 12-month 0O14 call and sell a higher strike (debit call spread) sized to equal 1.5% NAV max loss. This gives ~3x upside if the market re-rates on volume/currency stabilization while capping downside to premium paid.
• Short small-cap rare-disease / immuno-therapy peer (IMNM): small tactical hedge (0.5–1% NAV, 6–12 months) against class-competition and launch execution risk. Use this to offset binary downside if pipeline/launches underperform and to benefit if market rotates away from headline-risk biotechs.
• FX hedge: buy USD exposure vs EUR via 3–6 month forwards or USD call options sized to 20–30% of Merck position. This reduces reported-earnings volatility from EUR translation and monetizes the expected sensitivity to USD moves over the next two quarters.
• Income play for patient capital: sell 3-month OTM puts on 0O14 at strikes ~8–10% below current levels to collect premium, but size at no more than 2% NAV and pair with the long equity/option spread to cap assignment risk. Acceptable if willing to accumulate on deeper weakness.